Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) posted its quarterly earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32), Zacks reports. During the same quarter in the previous year, the firm posted ($1.00) EPS.

Eledon Pharmaceuticals Stock Up 0.6 %

Shares of ELDN traded up $0.02 during mid-day trading on Friday, reaching $3.46. 56,806 shares of the stock traded hands, compared to its average volume of 275,260. The firm has a market cap of $206.70 million, a price-to-earnings ratio of -1.73 and a beta of 0.80. The stock has a fifty day simple moving average of $4.18 and a 200 day simple moving average of $3.85. Eledon Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $5.54.

Analyst Ratings Changes

Separately, Guggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price objective on the stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).